200 related articles for article (PubMed ID: 35408914)
1. Mechanistic Insight into the Mode of Action of Acid β-Glucosidase Enhancer Ambroxol.
Pantoom S; Hules L; Schöll C; Petrosyan A; Monticelli M; Pospech J; Cubellis MV; Hermann A; Lukas J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408914
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.
Khanna R; Benjamin ER; Pellegrino L; Schilling A; Rigat BA; Soska R; Nafar H; Ranes BE; Feng J; Lun Y; Powe AC; Palling DJ; Wustman BA; Schiffmann R; Mahuran DJ; Lockhart DJ; Valenzano KJ
FEBS J; 2010 Apr; 277(7):1618-38. PubMed ID: 20148966
[TBL] [Abstract][Full Text] [Related]
4. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice.
Luan Z; Li L; Higaki K; Nanba E; Suzuki Y; Ohno K
Brain Dev; 2013 Apr; 35(4):317-22. PubMed ID: 22682976
[TBL] [Abstract][Full Text] [Related]
5. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
[TBL] [Abstract][Full Text] [Related]
6. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
[TBL] [Abstract][Full Text] [Related]
7. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.
Sawkar AR; Cheng WC; Beutler E; Wong CH; Balch WE; Kelly JW
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15428-33. PubMed ID: 12434014
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.
Kim YM; Yum MS; Heo SH; Kim T; Jin HK; Bae JS; Seo GH; Oh A; Yoon HM; Lim HT; Kim HW; Ko TS; Lim HS; Osborn MJ; Tolar J; Cozma C; Rolfs A; Zimran A; Lee BH; Yoo HW
J Med Genet; 2020 Feb; 57(2):124-131. PubMed ID: 31649052
[TBL] [Abstract][Full Text] [Related]
9. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
10. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
[TBL] [Abstract][Full Text] [Related]
11. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
[TBL] [Abstract][Full Text] [Related]
12. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy.
Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707
[TBL] [Abstract][Full Text] [Related]
14. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.
Jiang W; Yi M; Maegawa GHB; Zhang H
J Hum Genet; 2020 Mar; 65(3):345-349. PubMed ID: 31822786
[TBL] [Abstract][Full Text] [Related]
15. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
16. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.
Steet R; Chung S; Lee WS; Pine CW; Do H; Kornfeld S
Biochem Pharmacol; 2007 May; 73(9):1376-83. PubMed ID: 17217920
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
[TBL] [Abstract][Full Text] [Related]
18. A Fluorescent sp2-iminosugar with pharmacological chaperone activity for gaucher disease: synthesis and intracellular distribution studies.
Luan Z; Higaki K; Aguilar-Moncayo M; Li L; Ninomiya H; Nanba E; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chembiochem; 2010 Nov; 11(17):2453-64. PubMed ID: 21064079
[TBL] [Abstract][Full Text] [Related]
19. Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review.
Higashi K; Sonoda Y; Kaku N; Fujii F; Yamashita F; Lee S; Tocan V; Ebihara G; Matsuoka W; Tetsuhara K; Sonoda M; Chong PF; Mushimoto Y; Kojima-Ishii K; Ishimura M; Koga Y; Fukuta A; Tsuchihashi NA; Kikuchi Y; Karashima T; Sawada T; Hotta T; Yoshimitsu M; Terazono H; Tajiri T; Nakagawa T; Sakai Y; Nakamura K; Ohga S
Mol Genet Genomic Med; 2024 Apr; 12(4):e2427. PubMed ID: 38553911
[TBL] [Abstract][Full Text] [Related]
20. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
